ChemRar Research and Development Institute

ChemRar Research and Development Institute is a prominent Russian private research center and investment group specializing in the discovery, development, and commercialization of innovative small molecule therapeutics. Operating as a high-tech hub, the institute integrates medicinal chemistry, high-throughput screening, and preclinical development with full-scale GMP manufacturing capabilities. The organization gained international recognition for the rapid development and production of Avifavir, one of the first registered treatments for COVID-19 globally. Beyond antivirals, ChemRar maintains a diverse pipeline focused on central nervous system disorders, endocrinology, and infectious diseases. The institute serves as a critical bridge between academic research and industrial application within the Russian pharmaceutical landscape, frequently partnering with international biopharma companies and sovereign wealth funds.